Literature DB >> 29885948

Targeted protein degradation and the enzymology of degraders.

Stewart L Fisher1, Andrew J Phillips2.   

Abstract

Targeted protein degradation is an emerging strategy for drug discovery that employs small molecules to catalyze the ubiquitination of target proteins, ultimately causing their degradation by the proteasome. Current degrader designs employ hetero-bivalent molecules to recruit E3 ubiquitin ligases such as VHL, Cereblon, and the IAPs to the target protein to be ubiquitinated. In this review, we describe some of the foundational studies underpinning the use of heterobivalent degraders for targeted protein degradation. We also present a framework for degraders as programmable essential activators of ubiquitin ligase enzymes, connecting their features as catalysts with established enzymology concepts.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29885948     DOI: 10.1016/j.cbpa.2018.05.004

Source DB:  PubMed          Journal:  Curr Opin Chem Biol        ISSN: 1367-5931            Impact factor:   8.822


  31 in total

1.  Targeted Degradation of a Hypoxia-Associated Non-coding RNA Enhances the Selectivity of a Small Molecule Interacting with RNA.

Authors:  Matthew G Costales; Blessy Suresh; Kamalakannan Vishnu; Matthew D Disney
Journal:  Cell Chem Biol       Date:  2019-05-23       Impact factor: 8.116

Review 2.  Advances in targeting 'undruggable' transcription factors with small molecules.

Authors:  Matthew J Henley; Angela N Koehler
Journal:  Nat Rev Drug Discov       Date:  2021-05-18       Impact factor: 84.694

Review 3.  Novel Agents in Multiple Myeloma.

Authors:  Raphaël Szalat; Nikhil C Munshi
Journal:  Cancer J       Date:  2019 Jan/Feb       Impact factor: 3.360

4.  Correlating Drug-Target Residence Time and Post-antibiotic Effect: Insight into Target Vulnerability.

Authors:  Shabnam Davoodi; Fereidoon Daryaee; Andrew Chang; Stephen G Walker; Peter J Tonge
Journal:  ACS Infect Dis       Date:  2020-02-14       Impact factor: 5.084

5.  A kinetic proofreading model for bispecific protein degraders.

Authors:  Derek W Bartlett; Adam M Gilbert
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-10-22       Impact factor: 2.745

Review 6.  PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.

Authors:  Mariell Pettersson; Craig M Crews
Journal:  Drug Discov Today Technol       Date:  2019-02-13

Review 7.  Emerging modes-of-action in drug discovery.

Authors:  Eric Valeur; Frank Narjes; Christian Ottmann; Alleyn T Plowright
Journal:  Medchemcomm       Date:  2019-06-25       Impact factor: 3.597

8.  Evolution of Cereblon-Mediated Protein Degradation as a Therapeutic Modality.

Authors:  Philip P Chamberlain; Laura A D'Agostino; J Michael Ellis; Joshua D Hansen; Mary E Matyskiela; Joseph J McDonald; Jennifer R Riggs; Lawrence G Hamann
Journal:  ACS Med Chem Lett       Date:  2019-11-12       Impact factor: 4.345

Review 9.  The Chemical Biology of Reversible Lysine Post-translational Modifications.

Authors:  Zhipeng A Wang; Philip A Cole
Journal:  Cell Chem Biol       Date:  2020-07-21       Impact factor: 8.116

Review 10.  Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality.

Authors:  Milka Kostic; Lyn H Jones
Journal:  Trends Pharmacol Sci       Date:  2020-03-26       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.